Skip to main content
Premium Trial:

Request an Annual Quote

As Expected, Nasdaq Issues Sequenom Delisting Notice

NEW YORK, March 22 (GenomeWeb News) - As expected, the Nasdaq exchange has notified Sequenom that its common stock is now subject to delisting due to its noncompliance with the exchange's $1.00 minimum closing bid price requirement, the company said today.


The notice comes less than a week after Sequenom was unable to meet its Nasdaq-imposed minimum requirement for continued listing when it failed to lift its shares above $1 for at least 10 consecutive trading days over the past six months.


Sequenom said that it plans to request a hearing before the Nasdaq Listing Qualifications Panel to review the determination to delist its common stock and to seek continued listing of its common stock on Nasdaq. The hearing is expected to be scheduled within 30 to 45 days of the request, Sequenom said. Sequenom will remain listed on the exchange during the appeal process.


As GenomeWeb News reported last September, the company had until March 15 to comply with the minimum bid requirement.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.